Global Neurology Summit 2024 – Webcast

The Global Neurology Summit 2024 brought together leading experts to explore transformative advances across epilepsy, stroke, multiple sclerosis, dementia, and headache syndromes. Featuring 13 sessions recorded for enduring material, the Summit offered a comprehensive review of the latest research, clinical strategies, emerging technologies, and ethical considerations shaping modern neurology.

The program delved into the interconnected mechanisms of neurological diseases, including neuroprotection, seizure burden assessment, wearable and predictive devices, neuromodulation, artificial intelligence, and breakthrough treatments in both adult and pediatric populations. Attendees engaged with diverse topics such as genetic therapies for epilepsy, deep brain stimulation in movement disorders, amyloid-targeted therapies in dementia, and AI integration in neurology practice.

Key learning goals included improving care through early diagnosis, optimizing pharmacologic and non-pharmacologic therapies, advancing individualized treatment, and bridging disparities in access to care. Expert-led sessions offered evidence-based approaches for primary care providers, neurologists, students, and specialists seeking continued education in complex neurological care.

This enduring activity provides a deep dive into neurological innovation, clinical decision-making, and technology-enhanced care delivery—ensuring learners stay at the forefront of neurologic practice while improving outcomes for patients with neurologic disorders.

Educational Objectives

• Explain the interconnected mechanisms in epilepsy and related brain diseases and discuss the concept of neuroprotection.
• Recognize disparities in epilepsy care and strategies to improve diagnosis, surgical referral, and access to treatment.
• Describe off-label and emerging uses of antiseizure medications and their mechanisms of action in neurological conditions.
• Compare genetic and personalized treatment approaches for epilepsy and evaluate their clinical applications and limitations.
• Summarize the clinical utility of predictive and wearable technologies in epilepsy and stroke management.
• Apply the 2024 McDonald Criteria for diagnosing multiple sclerosis and discuss novel therapies under investigation.
• Evaluate neuromodulation techniques in headache syndromes, epilepsy, and Parkinson’s disease, including indications and trial results.
• Discuss AI applications in dementia and epilepsy care, including benefits, limitations, and ethical considerations.
• Review the risks and benefits of emerging Alzheimer’s disease therapies, including amyloid antibody treatments.
• Improve patient and caregiver guidance in dementia diagnosis, prevention, and participation in clinical trials.

Who Should Do This Course?

This course is ideal for:

• Neurologists and Neurology Subspecialists (Epilepsy, Stroke, Dementia, Vascular Neurology, Pediatric Neurology).
• Psychiatry and Neurology professionals involved in dementia and seizure management.
• Primary Care Physicians and Geriatricians providing ongoing care for neurologic patients.
• Nurse Practitioners, Physician Assistants, and Neurology Nurses delivering neurologic and cognitive health care.
• Residents, Medical Students, and Students in allied health or neuroscience programs.

This course is particularly relevant for healthcare professionals integrating AI, neuromodulation, or genetic therapies into clinical practice.

Did You Know?

• Deep brain stimulation has shown over 50% seizure reduction in refractory epilepsy cases. (NEJM, 2010; Epilepsy Currents, 2021)
• Wearable stroke detection technologies are undergoing FDA evaluation for prehospital stroke triage. (Stroke, 2023)
• Amyloid antibody therapies have been linked to slower cognitive decline in Alzheimer’s patients but carry a risk of ARIA (Amyloid-Related Imaging Abnormalities). (JAMA Neurology, 2023)
• AI algorithms can detect seizure patterns with accuracy exceeding 90% in specific EEG applications. (Lancet Digital Health, 2022)
• Genetic testing for pediatric epilepsy can yield a definitive diagnosis in over 40% of cases. (Neurology Genetics, 2021)